ECO Animal Health Group plc (EAH) · 2026-09-17
ECOVAXXIN® MS has secured approval for its US field safety data following a trial in more than 170,000 commercial laying pullets. US marketing approval is expected by the end of the calendar year, advancing the vaccine towards launch.
ECO Animal Health Group plc (EAH) · 2026-09-08
ECO Animal Health has appointed Dr Didier Branellec as an independent non-executive director with immediate effect. The appointment adds board-level animal health sector experience, while Branellec holds no shares or other beneficial interest in the company.
ECO Animal Health Group plc (EAH) · 2026-08-12
ECO Animal Health signed a perpetual exclusive worldwide licence with Vaxinano for a late-stage sheep toxoplasmosis vaccine candidate, with upfront fee, milestone and royalty payments.
ECO Animal Health Group plc (EAH) · 2026-07-15
ECO Animal Health Group reported FY2026 revenue of £87.5m, up 10%, with adjusted EBITDA of £8.5m, up 16%, both ahead of upgraded market expectations. Gross margin rose to 49% and net cash ended at £25.4m.
ECO Animal Health Group plc (EAH) · 2026-07-02
ECO Animal Health has launched ECOVAXXIN® MS commercially across the European Union, with the official launch event in Madrid. The poultry vaccine is the first product from the company's proprietary R&D pipeline to reach commercial market entry.
ECO Animal Health Group plc (EAH) · 2026-06-04
ECO Animal Health Group renewed its £10m revolving credit facility and £5m overdraft, maintaining £15m in total banking facilities until June 2031. The company has not utilised the credit facility and expects to release audited full-year results in mid-July 2026.